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PULMONARY HYPERTENSION IN CHILDREN AND YOUNG ADULTS WITH 
SICKLE CELL DISEASE 
KRISTIN SHEPPARD 
ABSTRACT 
Introduction: Primary pulmonary hypertension (PH) is a progressive disease that 
is characterized by restricted blood flow in the pulmonary vasculature, resulting in an 
increase in pulmonary vascular resistance (PVR) (McLaughlin et al., 2009). Patients with 
sickle cell disease (SCD), a monogenic blood disorder that causes red blood cells to form 
a sickle shape and decreases their ability to carry oxygen to the body’s tissues, can 
develop secondary pulmonary hypertension. Although there is significant data showing 
that pulmonary hypertension secondary to SCD increases morbidity and mortality in 
adult patients, there is little information regarding how PH affects children with SCD 
(Klings & Machado et al., 2014). Although diagnosing PH requires right heart 
catheterization, the American College of Cardiology Foundation and the American Heart 
Association recommend using Doppler echocardiography as a screening test for PH 
(McLaughlin et al., 2009). A tricuspid valve regurgitant jet velocity (TRV) of 2.5 m/s or 
higher, measured by Doppler echocardiography, is suggestive of PH (McLaughlin et al., 
2009). Because Doppler echocardiography is non-invasive, there is much more 
information available regarding TRV than right heart catheterization, an invasive 
procedure. This study examines the prevalence and incidence of elevated TRV (≥ 2.5 
m/s) in children with SCD as well as factors that may be associated with an elevated 
TRV.  
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Materials and Methods: We conducted a retrospective longitudinal cohort study chart 
review for 83 subjects followed by pediatric hematology at Boston Medical Center; 
examining demographic information, pediatric and adult echocardiogram reports, SCD 
complications previously identified as being related to PH, laboratory results that have 
previously been identified as being related to PH while each subject was between the 
ages of 8 and 30 between July 31, 2003 and June 30, 2015. 
Results: We found that 11 (13%) of our study population had one or more elevated TRV 
value (≥ 2.5 m/s). Elevated TRV values ranged from 2.5 – 2.83 m/s. The average age for 
elevated TRV was 15.9 years old. Of the subjects with elevated TRV 6 (55%) were 
taking HU, as compared to 53 (64%) of the general study population. No SCD 
complications previously reported to be related to PH were found to be significantly 
associated with elevated TRV in our study population. The only laboratory value that we 
found to be associated with elevated TRV was an elevate reticulocyte count, with an 
average value of 11% of red blood cells in subjects with elevated TRV and 8.41% of red 
blood cells in the general study population (p = 0.04). 
Discussion/conclusion: We found that 13% of children with SCD had at least one 
screening echocardiogram with TRV ≥ 2.5 m/s, which is in agreement with the 
prevalence estimates of 10-20% published by the American Thoracic Society (Klings & 
Machado et al., 2014). However, this is much lower than the 30% reported in the 
literature (Kato, Onyekwere, & Gladwin, 2007). This may be caused by more widespread 
use of hydroxyurea therapy at our academic institution. We also found no associated 
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factors other than elevated reticulocyte count, while other studies found associations with 
a history of sepsis/bacteremia, history of ACS, history of asthma, Hb SS genotype, low 
hemoglobin levels, and elevated reticulocyte count (Hagar et al., 2007; Minniti et al., 
2009; Pashankar et al., 2008; Ambrusko et l., 2006; Kato et al., 2007)  
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INTRODUCTION 
 Primary pulmonary hypertension (PH) is a progressive disease that is 
characterized by restricted blood flow in the pulmonary vasculature, resulting in an 
increase in pulmonary vascular resistance (PVR) (McLaughlin et al., 2009). This disease 
was first described in 1891 as “pulmonary vascular sclerosis” by German physician, 
Ernst von Romberg (Barst, 2008). However, very little research was in this area until the 
late 1960’s when the use of the appetite suppressant, aminorex fumerate, caused an 
epidemic of chronic pulmonary hypertension in Austria, Germany, and Switzerland 
(Gurtner, 1984). In 1981 the National Heart, Lung, and Blood Institute supported a 
national registry for idiopathic pulmonary arterial hypertension, a form of primary 
pulmonary hypertension, which fueled the characterization of the clinical features and the 
natural history of this disease (Barst, 2008).  
Patients with sickle cell disease (SCD) can develop secondary pulmonary 
hypertension. Studies have shown that approximately 6 to 11% of adults with SCD have 
PH confirmed by right heart catheterization, and in these patients there is a 6-year 
mortality of 37% (Klings & Machado et al., 2014; Mehari, Gladwin, Tian, Machado, & 
Kato, 2012). There is little data regarding pulmonary hypertension in pediatric patients 
with SCD. Although there is significant data showing that pulmonary hypertension 
secondary to SCD increases morbidity and mortality in adult patients, there is little 
information regarding how PH affects mortality in children with SCD (Klings & 
Machado et al., 2014).  
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Although diagnosing PH requires right heart catheterization, the American 
College of Cardiology Foundation and the American Heart Association recommend using 
Doppler echocardiography as a screening test for PH (McLaughlin et al., 2009). A 
tricuspid valve regurgitant jet velocity (TRV) of 2.5 m/s or higher, measured by Doppler 
echocardiography, is suggestive of PH (McLaughlin et al., 2009). Because Doppler 
echocardiography is non-invasive, there is much more information available regarding 
TRV than right heart catheterization, an invasive procedure. However, several studies 
have shown that echocardiography has a low predictive value for PH, with only a 25% 
predictive value with TRV ≥ 2.5 m/s, and a 64% predictive value with TRV ≥ 2.9 m/s 
(Parent et al., 2011). The low availability of right heart catheterization data and the low 
predictive value of TRV ≥ 2.5 m/s makes it difficult to know the extent of PH among the 
SCD population.  
We conducted a retrospective longitudinal cohort study chart review to examine 
the prevalence and incidence of elevated TRV (≥ 2.5 m/s) in children with SCD as well 
as factors that may be associated with an elevated TRV. This study also aims to 
determine the change of TRV over time in response to SCD-directed therapies, including 
HU and chronic transfusions, in children with SCD. 
 
Normal Anatomy and Function of the Heart and Pulmonary Vasculature 
The heart and lungs pump blood through the body and provide oxygen to the 
body’s tissues (Figure 1). Deoxygenated blood collects in the right atrium via the inferior 
and superior venae cavae before moving through the tricuspid valve into the right 
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ventricle when the atrium contracts (Pappano & Wier, 2012). This period of ventricular 
filling is called diastole, and normal right ventricular diastolic pressure is between 3 and 
8 mmHg (Pappano & Wier, 2012). When the right ventricle contracts, the pressure forces 
the tricuspid valve closed, preventing backflow of blood and pushing the blood through 
the pulmonary valve into the pulmonary artery (Pappano & Wier, 2012). This period of 
ventricular contraction is called systole; normal right ventricular systolic pressure is 
between 15 and 30 mmHg (Pappano & Wier, 2012). Blood flows from the pulmonary 
arteries at a normal resting pressure between 12 and 16 mmHg into the pulmonary 
alveolar capillary plexuses surrounding the alveoli in the lungs (West, 2012). The 
pulmonary capillaries is where gas exchange occurs between the blood and the inspired 
air, with CO2 diffusing out of the blood and O2 diffusing into the blood and bound by 
hemoglobin (West, 2012). The oxygenated blood then moves into the pulmonary veins 
and into the left side of the heart (Pappano & Weir, 2012).  
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Figure 1. Blood flow through heart and pulmonary vessels. (A) Blood from the body 
collects in the right atrium moves into the right ventricle before it is pumped into the 
pulmonary arteries. It then moves through the pulmonary vessels and collects in the left 
atrium before moving into the left ventricle where it is pumped back into the body. (B) 
Blood from the right ventricle is pumped into the pulmonary artery where it moves into 
the alveolar capillary plexus to be oxygenated. It then moves into the pulmonary veins 
and collects in the left atrium of the heart. Adapted from Moore, Agur, & Dalley, 2011. 
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Primary Pulmonary Hypertension 
 Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure 
(mPAP) that is elevated above 25 mmHg at rest (Hoeper et al., 2013). The most common 
cause of primary PH is left-sided heart disease, which leads to an increase in pulmonary 
venous pressure, and results in an increase in post-capillary PVR (Lerner and Mandel, 
2014). This form of pulmonary hypertension is referred to as pulmonary venous 
hypertension. However, primary PH can also be caused by pathological changes in the 
pulmonary arteries. These arterial changes lead to an increase in pre-capillary PVR and 
can ultimately result in right-sided heart failure and is referred to as pulmonary arterial 
hypertension (PAH) (Runo & Loyd, 2003).  
 
Etiology and Histology of Pulmonary Hypertension 
 Pulmonary venous hypertension has three etiologies (Lerner and Mandel, 2014). 
The first is systolic heart failure caused by coronary artery disease, infiltrative disease, 
and congenital heart disease (Lerner and Mandel, 2014). Next is heart failure with 
preserved ejection fraction, meaning that the ejection fraction is normal, but there is 
abnormal left ventricular relaxation, filling, and distensibility (Lerner and Mandel, 2014). 
Finally, it can be caused by valvular disease, mainly mitral stenosis and aortic stenosis 
(Wilson et al., 2012; Lerner and Mandel, 2014).  
 All etiologies of pulmonary venous hypertension lead to passive PH (Lerner and 
Mandel, 2014). In passive PH the left atrial pressure is passively transmitted to the 
pulmonary artery system, causing the pulmonary capillary wedge pressure to increase 
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while the PVR remains normal (Guazzi and Borlaug, 2012). Chronic passive PH can 
progress to reactive PH, where both the pulmonary capillary wedge pressure and the PVR 
are increased (Guazzi and Borlaug, 2012). Reactive PH is characterized by congestive 
vasculopathy caused by cellular wall remodeling, impaired vascular reactivity, 
endothelial dysfunction, and abnormal smooth muscle tone (Guazzi and Borlaug, 2012; 
Guazzi, 2008; Delgado et al., 2005). Characteristic histological changes include medial 
hypertrophy, abnormalities in the elastic fibers of the arterial walls, and intimal fibrosis 
(Delgado et al., 2005). It is also characterized by arterialization of the pulmonary veins 
through growth factors, glycoproteins, and serine elastase causing smooth muscle growth 
(Graham et al., 2011).  
The increased PVR seen in PAH is caused by a decrease in the lumen cross-
sectional area of the pulmonary vasculature (McLaughlin et al., 2009). In the majority of 
cases, this is caused by excessive pulmonary arterial smooth muscle cells (PASMC) and 
endothelial cell proliferation and a decreased rate of apoptosis, which in turn leads to 
vascular remodeling (Figure 2) (McLaughlin et al., 2009). Studies have shown that 
abnormal hyperpolarization of mitochondria leads to the inappropriate activation of 
transcription factor HIF-1 while activated T-cells cause activation of transcription factor 
NFAT (Bonnet et al., 2006; Bonnet et al., 2007). The inappropriate activation of these 
transcription factors leads to the down-regulation of the voltage gated potassium channel, 
Kv1.5, in PASMC, which in turn causes depolarization of the PASMC and a subsequent 
influx of free Ca2+ through voltage gated calcium channels (Bonnet et al., 2006; Bonnet 
et al., 2007). The increased intracellular free calcium stimulates pulmonary 
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vasoconstriction and PASMC proliferation (Platoshyn et al., 2000). Apoptosis is also 
suppressed by de novo expression of the anti-apoptotic protein survivin in PASMC 
(McMurtry et al., 2005). Endothelial injury and inflammation may also play a role in 
vessel wall remodeling and cell proliferation through the activation of pro-inflammatory 
cytokines IL-1β and IL-6, which promote thrombosis and are potent mitogens 
(McLaughlin et al., 2009; Eddahibi, Morrell, d’Ortho, Maeije, & Adnot 2002). 
 
 
 
Figure 2. Pathways leading to vascular remodeling in PH. Activated T-cells cause the 
increased expression of NFAT while abnormal hyperpolarization of mitochondria causes 
an increase in expression of HIF-1. NFAT and HIF-1 expression cause downregulation of 
potassium channels and subsequently increased PASMC depolarization and increased 
intracellular free-calcium that increases proliferation and decreases apoptosis of 
endothelial cells and smooth muscle cells. Adapted from Bonnet et al., 2006; Bonnet et 
al., 2007; and Mclaughlin et al., 2009. 
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In approximately 20% of PAH patients, excessive vasoconstriction significantly 
contributes to the decreased luminal cross-sectional area (Figure 3) (McLaughlin et al., 
2009). There are 4 mechanisms that may contribute to this phenomenon. First, is a shift in 
balance has been found from prostacyclin, a vasodilator that inhibits platelet activation 
and has antiproliferative properties, towards thromboxane A2, a vasoconstrictor that 
promotes platelet activation and proliferation (Christman et al., 1992). This is supported 
by the decrease in prostacyclin synthase in the endothelial cells of small and medium 
sized pulmonary arteries of PH patients (Tuder et al., 1999). Second, reduced amounts of 
nitric oxide (NO), a vasodilator that contributes to basal pulmonary vascular tone, may 
also contribute to the excessive vasoconstriction in PAH (Stamler, Loh, Roddy, Currie, & 
Creager1994; Celermajer, Dollery, Burch, & Deanfield. 1994). It has been found that 
PAH patients have reduced amounts of NO synthase (NOS) in their lungs, and NOS 
knockout mice have substantially increased PVR that causes PH  (Giaid & Saleh, 1995; 
Steudel et al., 1997). Third, PAH patients have elevated plasma levels of Endothelin-1 
(ET-1), a vasoconstrictor that also stimulates smooth muscle cell proliferation, and 
plasma levels of ET-1 correlate with severity and prognosis of PAH (Rubens et al., 
2001). Fourth, plasma levels of serotonin, a vasoconstrictor that promotes PASMC 
hypertrophy and hyperplasia, are increased in PAH patients (McLaughlin et al., 2009). A 
polymorphism in the gene for the serotonin transporter is present in approximate 70–80% 
of PH patients as opposed to 20–30% of the general population (Eddahibi et al., 2001). 
This polymorphism causes an increase in expression of the serotonin transporter in 
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platelets and lung tissue, though this likely indicates susceptibility to PH as opposed to 
causation (Eddahibi et al., 2001).  
 
Figure 3. Effect of excessive vasoconstriction in PH. An imbalance in vasoconstrictors 
and vasodilators causes sustained and excessive constriction of pulmonary blood vessel, 
resulting in a decrease in luminal cross-sectional area. Adapted from Wilkins, 2012. 
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considered to be a hallmark of PAH (Archer & Rich, 2000; Jonigk et al., 2011). These 
plexiform lesions show up-regulation of remodeling associated genes including HIF-1α, 
TGF-β, vascular endothelial growth factor-α (VEGF-α), VEGF receptors, Ang-1, Tie-2, 
and THBS1 (Archer & Rich, 2000; Jonigk et al., 2011). They also show markers for 
vascular sprouting, a mechanism for creating new vasculature, including NOTCH and 
matrix metalloproteinases (Archer & Rich, 2000; Jonigk et al., 2011). 
 
 
Diagnosis of Pulmonary Hypertension 
Symptoms of PH include: exertional dyspnea, fatigue, weakness, dyspnea at rest, 
edema, ascites, anorexia, chest pain, palpitations, or syncope (McGoon et al., 2004; 
Lourenço, Fontoura, Henriques-Coelho, & Leite-Moreira, 2012). The definitive diagnosis 
of PH requires the finding of mPAP above 25 mmHg at rest during right heart 
catheterization (McGoon et al., 2004). Given the cost and risks associated with right heart 
catheterization, non-invasive screening methods, namely transthoracic Doppler 
echocardiography, are used to screen for PH when it is suspected from clinical 
presentation. If PH is suspected, the American College of Cardiology Foundation and the 
American Heart Association recommend screening for PH with echocardiography 
(McLaughlin et al., 2009).  
Doppler echocardiography can be used to approximate the mPAP. This is done 
through the use of the modified Bernoulli’s formula: 
sPAP = 4(TRV)2 + RAP 
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where sPAP is the systolic pulmonary artery pressure, TRV is the tricuspid valve 
regurgitation velocity, and RAP is the right atrial pressure (Pyxaras et al., 2011). RAP is 
estimated through the use of inferior vena cava diameter and inferior vena cava 
collapsibility index (Beigel, Cercek, Luo, & Siegel, 2013). After the sPAP is estimated, it 
can be used to estimate the mPAP with the following equation: 
mPAP = 0.61(sPAP) + 2 mmHg 
Other findings in echocardiography that may be suggestive of PH include right atrial 
enlargement, right ventricular dilation or hypertrophy, a right-to-left septum shift, and a 
TRV elevated to ≥ 2.5 m/s (Klings & Machado et al., 2014; McLaughlin et al., 2004).  
 Although echocardiography can be a useful screening tool for PH, it is imperfect. 
One study found that the positive predictive value for PH with TRV elevated to 2.5 m/s 
or above on Doppler echocardiography was only 25%, and improved to 64% when the 
TRV threshold was raised to 2.9 m/s or higher (Parent et al., 2011). Another study found 
that Doppler echocardiography was inaccurate in the estimation of sPAP when compared 
to right heart catheterization in 48% of cases (Fisher et al., 2009). Because of these 
imperfections, Doppler echocardiography remains useful for screening, but right heart 
catheterization remains the gold standard for diagnosis.   
 
Classification of Pulmonary Hypertension 
The Fifth World Symposium on Pulmonary Hypertension established clinical 
classifications to categorize PH into five groups that share similar pathological findings, 
hemodynamic characteristics, and management (Table 1) (Simonneau et al., 2013). In 
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Group 1 PH, individuals have pulmonary arterial hypertension (PAH) in the setting of a 
normal left ventricular filling pressure; they often has a transpulmonary gradient elevated 
above 12 mmHg (Simonneau et al., 2013; Lourenço et al., 2012; Klings & Machado et 
al., 2014). The incidence of PAH is 2.4 to 7.6 cases per million per year, with a 
prevalence of 15 to 26 cases per million (Lourenço et al., 2012). Group 2 PH contains PH 
due to left-sided heart disease (Simonneau et al., 2013). This is also known as pulmonary 
venous hypertension and is characterized by elevated pulmonary venous pressures 
secondary to left atrial hypertension (Lerner & Mandel, 2014). It has the additional 
characteristic of a pulmonary capillary wedge pressure greater than 15 mmHg (Lerner & 
Mandel, 2014; Mehari et al., 2013; Klings & Machado et al., 2014). Group 3 contains 
pulmonary hypertension associated with lung disease or hypoxia, but the Fifth World 
Symposium on Pulmonary Hypertension did not distinguish if these were pulmonary 
venous hypertension or pulmonary arterial hypertension (Simonneau et al., 2013). Group 
4 includes chronic thromboembolic pulmonary hypertension, which is pulmonary 
hypertension caused by pulmonary thromboemboli (Lang and Madani, 2014).  Finally, 
Group 5 contains pulmonary hypertension with unclear multifactorial mechanisms 
including hematological disorders, systemic disorders, metabolic disorders, and other 
disorders (Simonneau et al., 2013). Pulmonary hypertension due to left heart disease 
(Group 2) is the most common of the different classes of pulmonary hypertension (Lerner 
& Mandel., 2014). However, there is little data regarding the incidence and prevalence 
for classes of pulmonary hypertension other than Group 1. 
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Table 1. Classification of Pulmonary Hypertension 
Classification 
Group 1: Pulmonary arterial hypertension 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.3 Drug and Toxin Induced PAH 
1.4 PAH associated with: 
・ Connective tissue disease 
・ HIV 
・ Portal hypertension 
・ Congenital Heart Disease 
・ Schistosomiasis 
Group 1’: Pulmonary veno-occlusive disease and/or pulmonary capillary hemagiomatosis 
Group 1”: Persistent pulmonary hypertension of the newborn 
Group 2: Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital or acquired left heart inflow or outflow tract obstruction and congenital 
cardiomyopathies  
Group 3: Pulmonary hypertension due to lung disease and/or hypoxemia  
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitudes  
3.7 Developmental lung diseases 
Group 4: Chronic thromboembolic pulmonary hypertension 
Group 5: Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders:  
・ Chronic hemolytic anemia 
・ Myeloproliferative disorders 
・ Splenectomy  
5.2 Systemic disorders: 
・ Sarcoidosis 
・ Pulmonary histiocytosis 
・ Lymphangioleiomyomatosis 
5.3 Metabolic disorders: 
・ Glycogen storage disease 
・ Gaucher disease 
・ Thyroid disorders 
5.4 Other: 
・ Tumoral obstruction 
・ Fibrosing mediastinitis 
・ Chronic renal failure 
・ Segmental PH 
Adapted from Simonneau et al., 2013 
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Prognosis 
 Prognosis after diagnosis of PH through right heart catheterization is variable 
based on the underlying etiology (McLaughlin et al., 2009). For primary PH of all 
etiologies, the survival rate is 79% one year after diagnosis, and declines to 29% four 
years after a diagnosis is made (McLaughlin et al., 2004). Idiopathic PAH (Group 1) and 
PAH related to HIV (Group 1) have similar prognoses, with one-year survival and three-
year survival of 77% and 35%, respectively (McLaughlin et al., 2009). Those with PAH 
related to the scleroderma spectrum of diseases (Group 1) have a much worse prognosis, 
with only 40% survival two years after diagnosis (McLaughlin et al., 2009). However, 
those with PAH related to congenital heart disease (Group 1) have a much better 
prognosis with 77% survival after 3 years (McLaughlin et al., 2009).  
There are several factors that contribute to the prediction of poor prognosis across 
all etiologies of PH. One of these predictors is the World Health Organization’s 
functional classifications, where a more advanced functional class indicates higher 
impact on the patient’s life and a worse prognosis (Table 2) (Taichman et al., 2014). 
Other predictors of poor prognosis include poor exercise capacity indicated by 6-minute 
walk distance test or cardiopulmonary exercise test, high right atrial pressure, significant 
right ventricular dysfunction, evidence of right ventricular failure, low cardiac index, or 
elevated brain natriuretic peptide (McLaughlin et al., 2009).  
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Table 2. World Health Organization Functional Classifications for Pulmonary 
Hypertension 
Class I PH does not limit physical activity. Ordinary physical does not cause undue dyspnea, 
fatigue, chest pain, or near syncope. 
Class II PH causes slight limitation of physical activity, though the patient is comfortable at rest. 
Ordinary physical activity may cause undue dyspnea or fatigue, chest pain or near syncope. 
Class III PH causes severe limitation of physical activity, though the patient is comfortable at rest. 
Less than ordinary physical activity causes undue dyspnea or fatigue, chest pain or near 
syncope. 
Class IV PH causes the inability to carryout any physical activity, and may show signs of right heart 
failure. Dyspnea and/or fatigue may be present at rest, and discomfort is increased with any 
physical activity. 
Adapted from Taichman et al., 2014 
 
Treatment of Pulmonary Hypertension 
 Current treatment for PH can be both for management of symptoms and for the 
underlying etiology. For all five groups of PH, the American College of Cardiology 
Foundation and the American Heart Association recommend as general measures low 
level graded aerobic exercise such as walking, a sodium restricted diet (less than 2,400 
mg per day), obtaining routine vaccinations such as influenza and pneumococcal 
pneumonia, and avoiding pregnancy (McLaughlin et al., 2009). The American College of 
Cardiology and the American Heart Association also recommend diuretics for managing 
right ventricular volume overload, calcium channel blockers if the patient has a positive 
acute vasodilator response, and warfarin anticoagulation therapy for all patients with 
idiopathic PAH (Group 1) (McLaughlin et al., 2009). One study found that with 
pharmaceutical therapy targeted to PAH (Group 1) there was an 85% survival rate within 
the first year (Thenappan, Shah, Rich, & Gomberg-Maitland 2007).  
For patients with Group 1 PH there are targeted PAH therapies available that 
include several classes of pharmaceuticals including prostanoids, endothelial receptor 
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antagonists, Phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase 
stimulators (Figure 4) (McLaughlin et al., 2009). The first class of pharmaceuticals used 
for PAH targeted therapy is prostanoids. Prostanoids are synthetic analogues of 
prostacyclin, also called prostaglandin I2 (Humbert & Ghofrani, 2015). Prostaglandin I2 is 
naturally produced by endothelial cells and acts by binding to the IP receptors expressed 
in vascular smooth muscle cells, which initiates the conversion of adenosine triphosphate 
(ATP) to cyclic adenosine monophosphate (cAMP) (Humbert & Ghofrani, 2015). The 
cAMP acts as a second messenger and increases protein kinase A activity, which in turn 
initiates downstream effects that culminate in vasodilation (Humbert & Ghofrani, 2015). 
Prostaglandin I2 also has antithrombitic, antiproliferative, antimitogenic, and 
immunomodulatory properties (Humbert & Ghofrani, 2015; Clapp et al., 2002; Akagi et 
al., 2013). Prostanoids currently approved for use in PAH patients include epoprostenol, 
treprostinil, iloprost, and beraprost (Humbert & Ghofrani, 2015).  Selexipag is another 
prostanoid, but it is in clinical trials and has not yet been approved (Humbert & Ghofrani, 
2015).  
Endothelin receptor antagonists work by blocking endothelin receptor A and 
endothelin receptor B from being bound by endothelin-1, a potent vasoconstrictor that 
also promotes PASMC proliferation (Motte, McEntee & Naeije, 2006). Endothelin 
receptor A is mainly located in vascular smooth muscle cells, while endothelin receptor B 
is in both endothelial cells and vascular smooth muscle cells; both contribute to 
vasoconstriction and PASMC proliferation (Motte, McEntee & Naeije, 2006). Drugs in 
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this class of pharmaceuticals include bosentan, ambrisentan, and macitentan (Humbert & 
Ghofrani, 2015).  
The next class of pharmaceuticals is PDE-5 inhibitors. PDE-5 is highly expressed 
in the pulmonary vascular smooth muscle as well as in right ventricle cardiomyocytes, 
and converts cyclic guanosine monophosphate (cGMP) to guanosine monophosphate 
(GMP), preventing cGMP’s function as a second messenger to activate protein kinase G 
in order to trigger vasodilation and inhibit proliferation (Wilkins, Wharton, Grimminger, 
& Ghofrani, 2008). PDE-5 inhibitors prevent the degradation of cGMP and in turn 
promote vasodilation and inhibition of pulmonary vasculature smooth muscle cell 
proliferation (Wilkins et al., 2008). Drugs within this class of pharmaceuticals include 
sildenafil and tadalafil (Humbert & Ghofrani et al., 2015).  
The final class of pharmaceuticals approved for treatment of PAH is soluble 
guanylate cyclase stimulators. Soluble guanylate cyclase is an enzyme that binds NO and 
then converts guanosine triphosphate (GTP) to cGMP, which then acts as a second 
messenger to trigger vasodilation and inhibit vascular smooth muscle cell proliferation 
(Wilkins et al., 2008). Soluble guanylate cyclase stimulators act in two ways, first they 
sensitize soluble guanylate cyclase to endogenous NO by stabilizing the soluble 
guanylate cyclase-NO bond, second they directly stimulate soluble guanylate cyclase 
independent of NO in order to increase the generation of cGMP (Humbert & Ghofrani, 
2015). Currently, the only drug in this class of pharmaceuticals that has been approved 
for the treatment of PAH is riociguat (Humbert & Ghofrani, 2015). The World Health 
Organization recommends sequential combination therapy for the treatment of PAH, 
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meaning that a patient’s physician will add additional pharmaceuticals from other classes 
to the patient’s current treatment plan in order to improve their overall treatment 
(Humbert & Ghofrani, 2015). There have been several trials with sequential combination 
therapies showing varied results, these trials are summarized in Table 3.   
 
Figure 4. The molecular targets of approved PAH therapies. Prostanoids act by binding 
the IP receptor, and ultimately results in vasodilation and antiproliferative actions. 
Endothelin receptor antagonists work by inhibiting endothelin receptor A (ETRA) and 
endothelin receptor B (ETRB), which prevents vasoconstriction and PASMC 
proliferation. PDE5 inhibitors prevent the degradation of cGMP into GMP, and in turn 
prevent vasoconstriction and PASMC proliferation.  Soluble guanylate cyclase (sGC) 
stimulators promote the formation of cGMP, which in turn promotes vasodilation and 
prevents proliferation. Adapted from Humbert & Ghofrani, 2015. 
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Table 3. Summary of sequential combination therapy trials 
Successful Trials Unsuccessful Trials 
PACES: epoprostenol+ sildenafil 
(Simonneau et al., 2008) 
FREEDOM-C: ERAs or PDE-5 inhibitors + 
treprostinil 
(Tapson et al., 2012) 
TRIUMPH: bosentan + treprostinil 
(McLaughlin et al., 2010) 
PHIRST: bosentan + tadalafil 
(Galie et al., 2009) 
PATENT: ERAs or non-IV prostanoids + riociguat 
(Ghofrani et al., 2013) 
COMPASS-2: sildenafil + bosentan 
(Humbert & Ghofrani, 2015) 
SERAPHIN: PDE-5 inhibitor or non-IV prostanoid 
+ macitentan  
(Pulido et al., 2013) 
NCT00323297: bosentan + sildenafil 
(Pfizer, 2014) 
STEP: bosentan + iloprost 
(McLaughlin et al., 2006) 
PATENT PLUS: sildenafil + riociguat 
(Galie et al., 2015) 
GRIPHON: PDE-5 inhibitors or ERAs + selexipag  
(McLaughlin et al., 2015) 
 
Adapted from Humbert & Ghofrani et al., 2015 
 
For patients with Group 2 PH it is recommended to treat the underlying left heart 
disease (McLaughlin et al., 2009). Patients with Group 3 PH are recommended to treat 
the underlying chronic lung disease and hypoxemia (McLaughlin et al., 2009). Patients 
with Group 4 PH should be treated with anticoagulation therapy and may be considered 
for treatment with pulmonary thromboendarterectomy, a surgical procedure that removes 
thrombemboli from the pulmonary arteries in order to substantially lower the PVR and 
improve cardiac output (Hoeper, Mayer, Simmonneau, & Rubin, 2006). Treatment for 
group 5 PH varies based on the underlying cause. For example, patients with SCD are 
recommended to use SCD specific therapies such as hydroxyurea (HU) and chronic blood 
transfusions, and PAH targeted therapy is only recommended for individuals whose 
symptoms suggest that PAH-targeted therapies may have clinical benefits (Klings & 
Machado et al., 2014).  
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Sickle Cell Disease 
Genetics and Pathology 
Normal adult hemoglobin (Hb A) protein is composed of four globular subunits, 
two α-chains and two β-chains. Each subunit is composed of a protein chain and a heme 
group; the heme group contains an iron ion that reversibly binds oxygen, allowing 
oxygen to be transported from the lungs to the rest of the body (Marengo-Rowe, 2006). 
There are many variants of hemoglobin, though most are clinically insignificant and rare 
(Thom, Dickson, Gell, & Weiss, 2013). 
SCD is a term used to describe a 
group of genetic diseases that affect the 
hemoglobin within red blood cells. In 
SCD, at least one copy of the gene for the 
β-chain contains a mutation that causes 
glutamic acid, the amino acid in the sixth 
position, to be replaced with valine (Bunn, 
1997), and is referred to as sickle 
hemoglobin (Hb S) (Stuart & Nagel, 
2004). This mutation causes a 
hydrophobic motif that allows the β1 chain 
from one hemoglobin molecule to bind 
with a β2 chain from another hemoglobin molecule when they are in a deoxygenated 
state, forming long rods within the red blood cell (Figure 5) (Stuart & Nagel, 2004). This 
Figure 5. Hemoglobin S. S causes red 
blood cells to change from the normal 
biconcave disk to a sickle shape when 
oxygen is lost. Adapted from Bunn, 1997. 
   
 
 
21
causes the red blood cell to change from its normal biconcave disc into a sickle-shaped 
cell (Stuart & Nagel, 2004). These sickled cells have a decreased oxygen carrying 
capacity and can occlude blood vessels by adhering to endothelial cells in post-capillary 
venules as well as leukocytes causing the formation of a heterocellular aggregate, 
resulting in tissue hypoxia (Stuart & Nagel, 2004). This occlusion of the 
microvasculature (i.e., vaso-occlusion) can occur anywhere in the body and can affect 
any organ (Stuart & Nagel, 2004). The combination of Hb S with any variant that is not 
Hb A results in SCD (Driscoll, 2007).  
 Patients that are homozygous for the Hb S gene (Hb SS genotype) typically have 
the most severe form of the disease. Red blood cells exclusively contain Hb S and have 
the potential to polymerize and cause the cell to form the sickle shape, and the rate and 
extent of polymerization is proportional to the duration and extent of deoxygenation 
(Rees, Williams, & Gladwin, 2010). The Hb SS genotype reduces the lifespan of a red 
blood cell from 100 - 120 days to 7 – 12 days (Bender & Hobbs, 2012).  
 The Hb SC genotype tends to be clinically milder than the Hb SS genotype. In 
this form of SCD, the patient is a double heterozygote for Hb S and Hb C, meaning that 
they inherit the Hb S gene from one parent and the Hb C gene from the other parent 
(Stuart & Nagel, 2004). In the Hb C mutation, the amino acid lysine replaces glutamic 
acid at the sixth position in the β-chain (Nagel, Fabry, & Steinberg, 2003). Hb C causes 
the red blood cell to lose water and potassium ions (K+) due to high potassium-chloride 
co-transport activity, which causes dehydration of the red blood cell and concentration of 
the hemoglobin (Nagel, Fabry, & Steinberg, 2003). This dehydration and subsequent 
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concentration of hemoglobin increases the tendency of Hb S to polymerize and the red 
blood cells to sickle (Nagel, Fabry, & Steinberg, 2003).  
 In the Hb Sβ-thalassemia genotypes, the patient is a double heterozygote for HbS 
and β-thalassemia. β-thalassemia is a disease that causes either decreased or no 
production of the β-chain, resulting in either a reduced number of normal hemoglobin 
(β+-thalassemia) or no normal hemoglobin (β0-thalassemia) (Galanello & Origa, 2010). 
Patients with the Hb Sβ+-thalassemia genotype will have a reduction of normal β-chains 
in their hemoglobin, which results in a clinical course similar to that of the Hb SC 
genotype (Clarke & Higgins, 2000; Galanello & Origa, 2010). Those with the Hb Sβ0-
thalassemia genotype produce no normal hemoglobin, resulting in a more severe clinical 
course that mimics the Hb SS genotype (Clarke & Higgins, 2000; Galanello & Origa, 
2010).  
 
Prevalence 
 SCD is the most common monogenic disease worldwide (Weatehrall, Hofman, 
Rodgers, Ruffin, & Hrynkow, 2005). It is widespread in sub-Saharan Africa, and in the 
Middle East and India, with Hb S carrier frequencies ranging from 5–40% of the 
population in those regions (Figure 6) (Weatherall & Clegg, 2001). SCD is also seen in 
variable frequencies in countries such as the Brazil, Caribbean countries, and Central 
American countries where there have been major population movements from African 
countries, with an estimated frequency of heterozygotes between 5 and 25% (Weatherall 
et al., 2005).  In the United States, approximately 89,000 individuals are affected 
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(Brousseau, Panepinto, Nimmer, & Hoffmann, 2010). In the United States of America, 
SCD mainly affects individuals of African and Hispanic descent, with an incidence of 
73.1per 1,000 African American newborns and 6.9 per 1,000 Hispanic newborns, 
compared to 3.0 per 1,000 white newborns (Ojodu, Hulihan, Pope, & Grant, 2014). 
 
 
 
Figure 6. Hb S allele frequency worldwide. The allele frequency is highest in sub-
Saharan Africa, but varies in areas where there have been large populations movements 
from African countries. Adapted from Piel et al., 2013. 
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Complications 
 SCD is a progressive, debilitating disease with many complications (Table 4). 
Complications of SCD arise in infancy, as levels of fetal hemoglobin decline and the 
levels of Hb S increase, between 6 and 9 months of age (Oneal et al., 2006). When cells 
containing Hb S enter into areas of the body with lower blood oxygen levels they can 
take the sickle shape, adhere to blood vessel as well as to leukocytes, and create an 
occlusion of the microvasculature called vaso-occlusive events (VOEs) (Stuart & Nagel, 
2004; Steinberg, 1999). These VOEs are responsible for acute episodes of severe bony 
pain, commonly located in the extremities, back, and chest (Steinberg, 1999). Vaso-
occlusion in other organs can lead to severe, life-threatening complications, including 
acute chest syndrome (ACS), stroke, and splenic sequestration (Steinberg, 1999). Other 
vaso-occlusive complications include priapism which often leads to impotence; chronic 
kidney damage or nephropathy; microvascular eye disease or retinopathy; leg ulcers, and 
avascular necrosis of the hips or shoulders (Bender & Hobbs, 2012; Rees et al., 2010; 
Gladwin & Vichinsky, 2008; Steinberg, 1999).  
Red blood cells containing sickle hemoglobin are abnormally fragile, lasting 7-14 
days compared to the 120-day lifespan of a normal red blood cell (Steinberg, 1999). This 
high rate of red blood cell breakdown, or hemolysis, is also associated with complications 
of SCD, including anemia; cholelithiasis, due to the excess bilirubin released from the red 
blood cells; and acute aplastic episodes, a form of anemia where the bone marrow is not 
producing enough red blood cells (Steinberg, 1999).  
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Table 4. Common complications of SCD 
Complication Features Frequency 
Vaso-occlusive complications 
Vaso-occlusive 
events 
Pain caused by entrapment of red 
blood cells and leukocytes in the 
microcirculation resulting in vascular 
obstruction and ischemia. 
More than 70% of all patients with SCD 
Acute chest 
syndrome 
A new alveolar pulmonary infiltrate 
that is caused by a combination of 
infection, fat embolism from the bone 
marrow, and vaso-occlusion of the 
pulmonary vasculature.  
40% of all patients with SCD 
Stroke 
Death of brain cells caused by 
ischemia in the brain. 
10 % of children with SCD 
Splenic sequestration 
An acutely enlarged spleen with 
hemoglobin more than 2g/dL below 
the baseline. Can rapidly progress to 
shock and death 
Occurs in 10 – 30% of children with 
SCD 
Priapism 
Painful and unwanted erections that 
occur spontaneously, during 
nocturnal erections, or with fever and 
dehydration 
10 – 40% of men with SCD 
Nephropathy 
Damage to the kidneys or kidney 
disease 
5 – 20% of adults with SCD 
Retinopathy 
Damage to the retina, the light 
sensing portion of the eye 
Rare in Hb SS, but occurs in 50% of 
adults with Hb SC 
Leg ulcers 
A slow-healing break in the skin of 
the leg 
20% of adults with Hb SS 
Avascular necrosis Death of bone tissue due to ischemia 10 – 50% of adults with SCD 
Complications of Hemolysis 
Anemia 
A temporary interruption of red blood 
cell production. 
 
Cholelithiasis 
Gallstones, hardened deposits in the 
biliary tract.  
Present in most adults, though often 
asymptomatic. 
Acute Aplastic 
Episodes 
Rapidly occurring severe anemia 
caused by infection from parovirus 
B19 
 
Infectious Complications 
Streptococcus 
pneumoniae sepsis 
An overwhelming immune response 
to a bacterial infection, can be life 
threatening 
10% of children younger than 5 years 
old with Hb SS 
Bender & Hobbs, 2012; Rees et al., 2010; Gladwin & Vichinsky, 2008; Vichinsky et al., 2000; Ohene-
Frempong et al., 1998; Steinberg, 1999 
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Mortality 
Patients with SCD often have an early mortality; the median life expectancy is 42 
years for males and 48 years for women with the Hb SS genotype, and the medium life 
expectancy is 60 years for males and 68 years for females with the Hb SC genotype (Platt 
et al., 1994). Approximately 19% of these deaths occur during a pain episode, 28% were 
related to pulmonary complications, and 16% were caused by kidney failure (Hamideh & 
Alvarez, 2013). SCD also leaves patients susceptible to infection and related 
complications, including sepsis and bacteremia, which was a leading cause of death in 
infants with Hb SS prior to the introduction of more effective vaccines over the past 15 
years (Steinberg, 1999). 
 
Treatments for SCD 
Current treatments for SCD include HU and chronic blood transfusions. HU has 
multiple mechanisms that contribute to its therapeutic affects for SCD, including 
increasing the production of fetal hemoglobin (Hb F) (Green & Barral, 2014). Hb F is 
composed of two α-chains and two γ-chains rather than β-chains (Platt, 2008). In fetuses, 
Hb F is expressed in order to deliver oxygen to the tissues of the unborn child; but toward 
the end of fetal development the adult form of hemoglobin is expressed and the amount 
of Hb F declines (Oneal et al., 2006). By the time the child is six months old, little Hb F 
is found in the blood (Oneal et al., 2006). However, some individuals have mutations that 
cause the expression of Hb F to continue into adulthood (Bank, 2006; Akinsheye et al., 
2011). The Cooperative Study of Sickle Cell Disease, the largest cohort study of SCD in 
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the US which followed 3751 individuals from 1979 to 1988, found that higher Hb F 
levels were inversely related to the incidence of VOE related pain crises and ACS 
(Vichinsky et al., 1997; Castro et al., 1994). It is hypothesized that the presence of fetal 
hemoglobin helps to reduce the concentration of Hb S and makes polymerization of the 
hemoglobin molecules less likely to occur (Rees et al., 2010). These findings led to the 
use of HU for the treatment of SCD (Platt et al., 1984). HU is a cytotoxic drug that was 
initially used to treat polycythemia vera by inhibiting cell division and therefore reducing 
the abnormally high hematocrit and platelet count (Platt, 2008). The benefit of HU use in 
SCD is threefold. First, it decreases the levels of Hb S containing red blood cells because 
they are produced by rapidly dividing progenitor cells, resulting in the increased 
production of Hb F-containing red blood cells, since they arise from progenitor cells that 
divide more slowly (Platt, 2008; Green & Barral, 2014). Second, as a cytotoxic agent, 
HU decreases the production of white blood cells and platelets, which are instrumental in 
pro-inflammatory cellular adhesion and vascular injury (Platt, 2008; Green & Barral, 
2014). Third, as HU is metabolized, it stimulates the production of NO, which in turn 
binds soluble guanylate cyclase to stimulate both vasodilation and Hb F production (Platt, 
2008). Through all of these mechanisms of action, HU therapy decreases the number of 
VOEs, decreases the number of ACS events, and reduces mortality associated with SCD 
(Charache et al., 1995; Steinberg et al., 2003). 
Chronic blood transfusions have been shown to reduce the risk of stroke, reduce 
the number of ACS events, and reduce the frequency of VOEs (Hirst & Wang, 2002; 
Miller et al., 2001). The STOP I and STOP II trials showed that regularly performed 
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blood transfusions every three to four weeks maintained levels of Hb S below 30% of 
total circulating blood and was able to reduce the risk of first stroke occurring by 70% 
(Adams, et al., 1998). However, chronic blood transfusions carry the risk of iron 
overload, serious allergic reactions, hemolytic reaction, volume overload, and 
alloimmunization (Klings & Machado et al., 2014).  
 
Pulmonary Hypertension Secondary to SCD 
 SCD-associated cor pulmonale, or right-sided heart enlargement caused by 
disease in the lungs or pulmonary vasculature, was first described in literature in 1936 
(Yater & Hansmann, 1936). However, the first cases of PH in SCD confirmed by right 
heart catheterization was not published until 1966 (Rubler & Fleisher, 1966). This report 
found biventricular hypertrophy, elevated pulmonary vascular resistance, absence of 
significant valvular disease, and sudden death caused by pulmonary infarction in two 
patients in their 40’s with SCD (Rubler & Fleisher, 1966). More recent studies have 
found that 6–11% of adult patients have pulmonary hypertension confirmed with right 
heart catheterization, however, approximately 30% of adults with the Hb SS genotype 
and 10–25% of adults with the Hb SC genotype have a TRV ≥ 2.5 m/s which is 
suggestive of PH but is not adequate to diagnose PH (Klings & Machado et al., 2014).  
PH secondary to SCD has characteristics of both PAH and pulmonary venous 
hypertension, and is part of Group 5 PH (Table 1) (Simonneau et al., 2013, Klings & 
Machado, et al., 2014; Mehari et al., 2013). Hemodynamic features include a mPAP ≥25 
mmHg, pulmonary artery wedge pressure ≥ 15 mmHg, an increased PVR due to the 
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lower baseline produced by the anemia induced cardiac output and low blood viscosity, 
and a TPG > 12 mmHg (Klings & Machado et al., 2014; Mehari et al., 2013). There are 
many proposed etiologies, including: 1) a sickle cell related vasculopathy resulting in 
hyperplasia of the intima and in situ thrombosis; 2) chronic hypoxemia that is 
exacerbated by sleep hypoventilation; 3) parenchymal and vascular injury resulting from 
repeated episodes of ACS; 4) systemic scavenging of NO by plasma free hemoglobin as a 
result of hemolysis; 5) elevated arginase activity causing a decrease in the 
arginase/ornithine ratio, resulting in a reduced amount of NO production (Oppenheimer 
& Esterly, 1971; Adedeji, Cespedes, Allen, Subramony, & Hughson, 2001; Castro, 1996; 
Ataga et al., 2004; Reiter et al., 2002; Jison & Gladwin, 2003; Morris et al., 2003). It is 
very likely that PH in SCD is caused by combinations of these proposed mechanisms 
(Oppenheimer et al., 1971; Adedeji et al., 2001; Castro, 1996; Ataga et al., 2004; Reiter 
et al., 2002; Jison & Gladwin, 2003; Morris et al., 2003).  
There are many findings associated with secondary PH with SCD. There is an 
associated decrease in prostacyclins and NO (vasodilators) and an increase in 
vasoconstrictors (prostaglandins and endothelins), which is also typical of primary PH 
(Christman et al., 1992). Laboratory markers and clinical measures associated with PH in 
SCD are summarized in Table 5.  
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Table 5. Laboratory markers and clinical values associated with secondary PH with SCD 
Increased laboratory values 
Blood urea nitrogen 
Lactate dehydrogenase (LDH) 
Uric acid 
γ-glutamyltransferase 
Direct bilirubin 
Indirect bilirubin 
Aspartate aminotransferase 
Iron 
Ferritin 
Reticulocyte count 
Decreased laboratory values 
Platelet count 
Hemoglobin level 
Hematocrit 
transferritin 
Clinical values 
Proteinuria 
Shorter six-minute walk distance 
≥ 10 blood transfusions 
Older age 
History of sepsis/bacteremia 
History of ACS 
History of asthma 
(Fonesca, Souza, Salemi, Jardim, & Gualandro, 2012; Ataga et al., 2006; Gladwin et al., 
2004; Hagar et al., 2007; Minniti et al., 2009) 
 
 
There is an increased morbidity and mortality for SCD patients with PH. Factors 
associated with increased mortality include a mPAP ≥ 25 mmHg, transpulmonary 
gradient ≥ 12 mmHg, 6 minute walk distance < 400 meters, WHO functional class of III 
or IV, and a TRV ≥ 2.5 m/s (Mehari et al., 2013; Gladwin et al., 2004). With a TRV 
elevated to between 2.5 and 2.9 m/s there is a rate ratio of mortality of 4.4, and that raises 
to 10.6 when TRV is elevated above 2.9 m/s (Gladwin & Vichinsky, 2008; Klings & 
Machado et al., 2014).  
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There are several treatment options for PH associated with SCD. The first 
treatment option is HU. In small studies, HU was found to decrease TRV as well as a 
decrease baseline LDH and reticulocyte count (Olnes et al., 2009). In addition, HU has an 
NO donor effect, enabling vasodilation (Cokic et al., 2006; Cocik, Andric, Stojilkovic, 
Noguchi, & Schechter, 2008; Huang, Kim-Shapiro, & King, 2004). An in vitro study 
showed that HU enhances phosphorylation of endothelial cell NOS, resulting in increased 
NOS activity and increased NO production (Cokic et al., 2006). Another study found in 
vivo evidence that HU induces the NO/cGMP pathway in endothelial progenitor cells 
(Cokic et al., 2008). HU has also been found to interact with catalase in the presence of 
H2O2 to produce a ferrous-NO catalase complex that subsequently releases NO (Huang et 
al., 2004). There has been shown to be a lower prevalence of PH in SCD patients that are 
taking HU (Ataga et al., 2004).  
Chronic transfusion therapy is another treatment option. It has been shown that 
chronic transfusion therapy reduces Hb S to less than 50% within weeks (Klings & 
Machado et al., 2014). The American Thoracic Society extrapolates that chronic 
transfusion therapy will reduce mortality from PH by reducing ACS, VOE, and 
hemolysis (Klings & Machado et al., 2014).  
The American Thoracic Society suggests the use PAH specific therapies when the 
patient’s symptoms suggest that these pharmeceuticals may yield clinical benefit (Klings 
& Machado et al., 2014). A prostacyclin agonist or an endothelin receptor antagonist are 
recommended for SCD patients with elevated PVR and normal pulmonary artery wedge 
pressure (Klings & Machado et al., 2014). In 2009 the ASSET trials studied the use of 
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bosentan, and endothelin-1 receptor antagonist, but stopped the trial early due to low 
enrollment (n = 26) (Barst et al., 2008). However, they did find a non-significant increase 
in cardiac output on bosentan compared to placebo, and that the drug was well tolerated 
at standard dose without an increase in VOE or other events (Barst et al., 2008). A small 
retrospective study (n = 14) done after the ASSET trials showed that there was a 
statistically significant increase in 6 minute walk distance and a trend of decreased TRV 
with the use of either bosentan or ambrisentan, both endothelin receptor antagonists 
(Minniti et al., 2009). However, the American Thoracic Society recommends against the 
use of Sildenafil, a PDE-5 inhibitor (Klings & Machado et al., 2014). Although small 
studies showed that sildenafil was able to improve exercise capacity, lower systolic 
pulmonary artery pressure, lower TRV, and improve functional class, the Walk-PHaSST 
trial was ended early because there was an increase in hospitalization rates for pain in 
patients taking sildenafil compared to those on the placebo (Machado et al., 2005; Derchi 
et al., 2005; Machado et al., 2011). 
There are conflicting data regarding the prevalence of PH in children with SCD. 
The American Thoracic Society reports that 10–20% of pediatric SCD patients have a 
TRV ≥ 2.5 m/s (Klings & Machado et al., 2014). However, a meta-analysis combining 
data from 11 small studies reports that 30% of pediatric patients with SCD have a TRV ≥ 
2.5 m/s (Kato et al., 2007). Notably, many of these studies were done retrospectively with 
little information indicating why patients were screened, therefore subject to screening 
bias toward more clinically severe cases (Hagar, Michlitsch, Gardner, Vichinsky, & 
Morris, 2007; Kato et al., 2007).  
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Children with SCD and an elevated TRV of 2.5 m/s or higher are 13 years old on 
average and more likely to have the Hb SS genotype (Hagar et al., 2007; Kato et al., 
2007; Gordeuk et al., 2011).  It appears that TRV elevated to 2.5 m/s or above does not 
have the same impact on mortality in pediatric patients as it does in adults (Hagar et al., 
2007; Kato et al., 2007; Gordeuk et al., 2011). It has been suggested that there is a 
different mechanism leading to an elevated TRV in children with SCD than there is in 
adults with SCD (Hagar et al., 2007; Kato et al., 2007; Gordeuk et al., 2011). When 
compared to adult populations, children with SCD and TRV ≥ 2.5 m/s are more likely to 
have had a history of sepsis or bacteremia, ACS, asthma or and other obstructive 
pulmonary disorders (Hagar et al., 2007; Kato et al., 2007; Gordeuk et al., 2011). In 
adults with SCD, TRV ≥ 2.5 m/s is associated with age, end organ disease, and hepatitis 
C (Hagar et al., 2007). However, both populations have been found to have an associated 
decrease in hemoglobin levels, increase in reticulocyte count, increase in bilirubin, and 
increase in LDH levels, indicating that hemolysis likely plays a role in both children and 
adults (Kato et al., 2007; Pashankar et al., 2008; Minniti et al., 2009).  Treatment of PH in 
children has not been well studied. One small study has shown that TRV may be able to 
be lowered to below 2.5 m/s with early detection and treatment with HU (Klings & 
Machado et al., 2014; Hagar et al., 2007; Pashankar, Carbonella, Bazzy-Asaad, & 
Friedman, 2008).  
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Aims of This Study 
Little information is available regarding PH in pediatric patients with SCD. 
Although there right heart catheterization is required to diagnose PH, Doppler 
echocardiography is a screening tool used to identify individuals with TRV ≥ 2.5 m/s, a 
risk factor for PH (Klings & Machado et al., 2014). Because it is a non-invasive 
procedure, there is much more TRV data available than right heart catheterization data. 
This study is a longitudinal cohort study chart review looking at pediatric and adult 
echocardiograms, as well as laboratory values and clinical values, in children and young 
adults with SCD. 
The first specific aim of this study is to determine the prevalence and incidence of 
elevated TRV (≥ 2.5 m/s). Next, this study aims to determine demographic and clinical 
factors associated with an elevated TRV. Finally, this study aims to determine the change 
of TRV over time in response to SCD-directed therapies, including HU and chronic 
transfusions, in children with SCD.  
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MATERIALS AND METHODS 
 
Study design 
We conducted a retrospective longitudinal cohort study chart review to examine 
the prevalence and incidence of elevated TRV (≥ 2.5 m/s) in children with SCD as well 
as factors that may be associated with an elevated TRV.   
 
Setting 
 
This study was performed at Boston Medical Center (BMC), an urban safety net 
institution caring for an underserved population, of which more than 80% are eligible for 
public insurance. Approximately 200 children and 250 adults with SCD are cared for by 
pediatric and adult hematologists, respectively, in our institution. 
 
Research participants  
Eligible subjects were identified using the registry of children with SCD that has 
been in place at Boston Medical Center since 2000.  We included individuals if they were 
between the ages of 8 and 17 between July 31, 2003 and June 30, 2015. We excluded 
those who did not have any echocardiograms in this time period. In addition, those with 
comorbidities that may predispose that individual to an early onset pulmonary 
hypertension were excluded from our study, including: congenital heart disease 
(McLaughlin et al., 2009), chronic lung disease (e.g. bronchopulmonary dysplasia) 
(Khemani et al., 2007), connective tissue disease (e.g. systemic lupus erythematosus) 
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(McLaughlin et al., 2009), vascular abnormalities (e.g. moya moya syndrome) (Scott & 
Smith, 2009, Dobson et al., 2002), and premature birth (<35 weeks gestation) (Khemani 
et al., 2007). For individuals with a history of pulmonary embolism, data collection was 
censored at the date of the first pulmonary embolism (Kasper et al., 1980; Becattini et al., 
2006). We also excluded echocardiograms performed during an emergency department 
visit or as an inpatient stay because VOEs and ACS have been shown to transiently 
elevate TRV (Machado et al., 2007).  
 
Data collection 
 A chart review was performed to examine the prevalence and incidence of 
elevated TRV measured by echocardiography in individuals with SCD. The electronic 
health record system (Centricity®, GE Systems) was adopted in 2002, and was used to 
collect outpatient data including demographic data and baseline data. Inpatient data was 
available in a separate electronic health record, Sunrise Clinical Manager® (Eclypsis). 
 Several types of data were collected from chart review. First, demographic data 
were collected, including: date of birth, gender, race, ethnicity, and SCD genotype. 
Second, data were collected on the presence and dates of sickle cell-related complications 
previously shown to be associated with elevated TRV, including: stroke, splenic 
sequestration and/or splenectomy, nephropathy, retinopathy, priapism, sepsis or 
bacteremia, iron overload, leg ulcers, asthma, obstructive sleep apnea, tonsillectomy 
and/or adenoidectomy, deep vein thrombosis, pulmonary embolism, microalbuminuria, 
and proteinuria (Gladwin et al., 2004; De Castro et al., 2008). Third, information was 
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gathered on therapies with the potential to lower TRV, namely hydroxyurea and chronic 
blood transfusions, and the dates they were initiated (Pashankar, Carbonella, Bazzy-
Asaad, & Friedman, 2008; Pashankar, Manwani, Lee, & Green, 2015; Detterich et al., 
2015). Fourth, laboratory data associated with elevated TRV were collected, including: 
baseline hemoglobin levels and baseline reticulocyte count (Pashankar, Carbonella, 
Bazzy-Asaad, & Friedman, 2008; Pashankar, Manwani, Lee, & Green, 2015; Detterich et 
al., 2015). Finally, data was collected on acute care utilization, including number of 
emergency department visits for VOEs, number of emergency department visits for ACS, 
number of hospital admissions for VOE, and number of hospital admissions for ACS 
because a history of VOE related crises has been shown to be related to PH (Hagar et al., 
2007).  
 For each pediatric echocardiogram, data was collected from reports stored on the 
electronic health record system, PWF. For each adult echocardiogram, data was collected 
from reports on Logician. Data collected for pediatric and adult echocardiograms are 
summarized in Table 6. 
 
Statsistics 
 For all categorical data, including demographic data, SCD related complications, 
history of proteinuria, and history of microalbuminuria the 2-tailed Fisher’s exact test 
was used. For hemoglobin levels and reticulocyte count the 2-tailed t-test assuming equal 
variances was used. 
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Table 6. Data collected from pediatric and adult echocardiogram reports 
 Pediatric Echocardiograms Adult Echocardiograms 
Left 
heart 
Atrial dilation Atrial size 
Ventricular dilation Aortic root size 
Ventricular hypertrophy 
Ventricular wall motion (normal vs. 
abnormal) 
Ventricular dysfunction 
Ventricular diastolic function (normal 
vs. abnormal) 
Ventricular systolic function (normal vs. 
abnormal) 
Ventricular internal diameter at end 
systole 
Ventricular end diastolic volume Z-score 
Ventricular internal diameter at end 
diastole 
Ventricular mass Z-score Ventricular mass index 
Ventricular mass to volume ratio Ventricular size 
Ventricular mass to volume Z-score Fractional shortening 
Ventricular ejection fraction Ventricular ejection fraction 
Right 
heart 
Atrial dilation Atrium size 
Gradient between right ventricle and right 
atrium 
Estimation of atrial pressure 
Does septal position predict right 
ventricular pressure more than half of the 
systemic blood pressure 
Atrial function (normal vs. abnormal) 
Ventricular hypertrophy Ventricular size 
Presence of ventricular systolic 
dysfunction 
Ventricular function (normal vs. 
abnormal) 
-- 
Estimation of ventricular systolic 
pressure 
Pulmonary artery size Z-score Pulmonary artery (normal vs. abnormal) 
-- 
Description of inferior vena cava 
(normal vs. abnormal) 
Valves 
Presence of aortic regurgitation 
Presence/severity of aortic valve 
regurgitation 
Presence of pulmonary regurgitation 
Presence/severity of pulmonary valve 
regurgitation 
Presence of tricuspid regurgitation 
Presence/severity of tricuspid valve 
regurgitation 
TRV 
Presence/severity of mitral valve 
regurgitation 
-- 
Presence/severity of aortic valve 
stenosis 
-- 
Presence/severity of pulmonary valve 
stenosis 
-- 
Presence/severity of tricuspid valve 
stenosis 
-- 
Presence/severity of mitral valve 
stenosis 
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Table 6. continued 
Other 
Pediatric echocardiograms (continued) Adult Echocardiograms (continued) 
Date of echocardiogram Date of echocardiogram 
Calculated age of individual at time of 
echocardiogram 
Calculated age of individual at time of 
echocardiogram 
Location of echocardiogram (inpatient, 
outpatient, emergency department) 
Location of echocardiogram (inpatient, 
outpatient, emergency department) 
Diagnosis Indication of echocardiogram 
Height -- 
Weight -- 
Body mass index -- 
Body surface area -- 
Presence of pericardial effusion Presence/severity of pericardial effusion 
Presence of trabeculations -- 
Systemic systolic blood pressure -- 
Systemic diastolic blood pressure -- 
Report author -- 
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RESULTS 
Patient Population and Demographics 
Figure 7 describes the individuals that were identified as potential subjects for this 
study. There were 210 individuals followed by BMC hematology with SCD and were 
between the ages of 8 and 30 years old between July 31, 2003 and June 30, 2015. 
Pediatric echocardiograms were defined as echocardiograms that were performed while 
the patient was between the ages of 8 and 17 years old. Of the initial 210 patients 
identified, 74 did not have any pediatric echocardiograms and were therefore excluded 
from the study, leaving 136 individuals. Of these 136 individuals 16 were excluded for 
co-morbid diagnoses including moya moya syndrome (6 individuals), premature birth < 
35 weeks gestation (5 individuals), connective tissue disease (3 individuals), chronic lung 
disease (2 individuals), congenital heart disease (1 individual), and death (1 individual). 
Of the remaining 118 individuals, only 83 had either a measured or calculated TRV value 
available for one or more of their echocardiograms. Not all of the screening 
echocardiograms for those 83 individuals had TRV documented, making many of the 
individual echocardiograms ineligible for the study even though the subject had one or 
more eligible echocardiograms overall.  
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Figure 7. Excluded individuals. Initially 210 individuals were identified as potential 
subjects for this study. 74 of those individuals were excluded for not having any 
echocardiograms between the ages of 8 and 17. An additional 16 individuals were 
excluded for other diagnoses including moya moya, premature birth, connective tissue 
diseases, chronic lung disease, congenital heart disease, and death. 35 of those individuals 
did not have an available TRV value. 
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 The characteristics of the study population are summarized in Table 7. 
Demographic data showed that 11 (13%) subjects were born prior to 1990, 54 (65%) 
subjects were born between 1990 and 1999, and 18 (21%) subjects were born in or after 
2000. There were 42 (51%) females; 68 (82%) subjects identified as black; and 9 (11%) 
identified as Hispanic or Latino. SCD history data showed that 61 (73%) subjects have 
the Hb SS genotype. There were 50 people with a history of ACS (59%), 18 (22%) 
subjects with a history of splenic sequestration and/or splenectomy, 14 (17%) people with 
a history of sepsis or bacteremia, 18 (22%) people with asthma. There were 53 (64%) 
people that have used HU at some point during our study period and 7 (8%) people that 
received chronic blood transfusions during our study period. Laboratory characteristics 
indicated that 9 (8%) people have a history of microalbuminuria and 6 (5%) people have 
a history of proteinuria. The average value for baseline hemoglobin level was 9.15 g/dL 
and the average value for baseline reticulocyte count was 8.11% of red blood cells.  
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Table 7. Study population characteristics  
  Total (%) 
n = 83 
Demographic variables 
Year of birth 
< 1990 11 (13) 
1990-1999 54 (65) 
≥ 2000 18 (22) 
Gender 
Female 42 (51) 
Male 41 (49) 
Race 
Black 68 (82) 
White 2 (2) 
Declined to Answer 11 (13) 
Answer Blank 2 (2) 
Ethnicity 
Not Hispanic or Latino 74 (89) 
Hispanic or Latino 9 (11) 
SCD history 
Genotype 
SS 61 (73) 
SC 21 (25) 
Sβ-Thalassemia0 1 (1) 
History of: 
Stroke 2 (2) 
Acute chest syndrome 50 (60) 
Splenetic sequestration or splenectomy 18 (22) 
Nephropathy 3 (4) 
Retinopathy 4 (5) 
Priapism (men) 5 (12) 
Sepsis or bacteremia 14 (17) 
Iron overload 3 (4) 
Leg ulcers 1 (1) 
Asthma 18 (22) 
Obstructive sleep apnea 15 (18) 
Tonsillectomy and/or adenoidectomy 11 (13) 
Medications 
 Hydroxyurea use 53 (64) 
 Chronic blood transfusions 7 (8) 
Laboratory characteristics 
Baseline 
Values: 
Baseline Hb 8.95 
Baseline reticulocyte count 8.41 
History of: 
Microalbuminuria 6 (7) 
Proteinuria 6 (7) 
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 Figure 8 illustrates the TRV values for all patients included in this study plotted 
according to age at the time of the echocardiogram. Eleven (13%) individuals had one or 
more TRV value at or above 2.5 m/s; three (27%) had a single elevated measurement 
while eight (73%) had two or more abnormal readings (Figure 9). In those with elevated 
TRV, values ranged from 2.50 m/s to 2.83 m/s. The average age at the time of an 
elevated TRV was 15.9 years. In those with elevated TRV, 9 (79%) had taken HU 
therapy at some point during the study period, and 6 (55%)were taking it at the time of 
echocardiogram reading of TRV ≥ 2.5 m/s. Characteristics of individuals with at least 
one TRV ≥ 2.5 m/s are summarized in Table 8.  Nine out of the eleven individuals with 
an elevated TRV had the Hb SS genotype, which is 15% of the individuals with the Hb 
SS genotype within our population. One individual had the Hb SC genotype, which is 5% 
of the individuals with the HB SC genotype within our study population, and one person 
had the Sβ0-Thalassemia genotype (the only individual with this genotype in our study 
population). Among these individuals the average baseline hemoglobin level was 8.3 
g/dL and the average reticulocyte count was 11% of red blood cells. The reticulocyte 
count was significantly increased when compared to subjects with TRV < 2.5 m/s (p = 
0.04). Eight (73%) of the individuals with one or more TRV ≥ 2.5 m/s had a history of 
ASC (p = 0.51), two (18%) had a history of splenic sequestration/ splenectomy (p = 
1.00), two (18%) had a history of sepsis/bacteremia (p = 1.00), one (9%) had a history of 
iron overload (p = 0.35), and two (18%) had a history of asthma (p = 1.00). However, 
none of these characteristics were found to have statistical significance when compared to 
subjects with TRV < 2.5 m/s. 
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Figure 8. TRV in m/s at the age of each echocardiogram for all individuals included in this study. TRV over time for each 
patient included in this study that had TRV measured as an outpatient by echocardiography. 11 individuals had TRV elevated 
to 2.5 m/s or above. Of those individuals, 8 had only one TRV ≥ 2.5 m/s. 
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Figure 9. TRV in m/s at the age of each echocardiogram for each individual with one or more TRV ≥ 2.5 m/s. The start of HU 
therapy is indicated for each individual by a solid vertical line. Subjects 47 and 119 were not shown because each had only one 
TRV available, and neither has ever been on HU therapy. 
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Table 8. Individuals with TRV ≥ 2.5 m/s and key characteristics  
Subject Genotype 
Baseline 
Hgb 
Baseline 
reticulocyte 
count 
SCD associated 
complications 
Number of 
Normal 
Echos 
Age at 
Abnormal 
Echo 
TRV 
(m/s) 
HU use 
at time of 
echo 
Chronic 
transfusion 
therapy at time of 
echo 
25 
Sβ0-
Thalassemia 
7.0 8.0 
ACS, splenic 
sequestration/splenectomy, 
sepsis/bacteremia, iron 
overload 
1 
16 2.7 No No 
18 2.7 Yes No 
22 2.5 Yes No 
47 SC 11.0 5.0 ACS 0 22 2.5 No No 
56 SS 7.0 8.0 ACS, asthma 2 17 2.6 Yes No 
64 SS 10.0 11.0 ACS 4 14 2.8 Yes No 
70 SS 9.0 13.0 
ACS, splenic 
sequestration/ splenectomy 
1 11 2.7 No No 
108 SS 7.0 12.0 ACS, sepsis/bacteremia 2 
12 2.5 Yes No 
15 2.6 Yes No 
114 SS 8.0 18.0 ACS 0 
13 2.8 No No 
17 2.6 No No 
119 SS 7.0 10.0 -- 0 26 2.5 No No 
176 SS 9.0 7.0 -- 1 13 2.5 Yes No 
192 SS 9.0 20.0 Asthma 4 12 2.5 No No 
195 SS 7.6 12.0 ACS 0 10 2.5 Yes No 
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DISCUSSION 
 
 In this 13-year retrospective longitudinal cohort study, we found that 13% of 
children with SCD between the ages of 8 and 17 years had at least one screening 
echocardiogram with TRV ≥ 2.5 m/s, which is in agreement with the prevalence 
estimates of 10-20% published by the American Thoracic Society (Klings & Machado et 
al., 2014).  
Our study found no complications of SCD of laboratory values to be significantly 
associated with TRV ≥ 2.5 m/s. While previous studies have reported significant 
differences in history of sepsis and/or bacteremia, ACS, and asthma; our study found no 
statistical significance between subjects with TRV ≥ 2.5 and TRV < 2.5 for these clinical 
histories (Hagar et al., 2007). Previous studies have also found that significant decreases 
in hemoglobin and increases reticulocyte counts are associated with TRV ≥ 2.5 m/s, our 
study found only an increase in reticulocyte count to be statistically significant (p = 0.04) 
(Minniti et al., 2009; Pashankar et al., 2008; Ambrusko et al., 2006; Kato et al., 2007).  
This study did not find SCD genotype or SCD directed therapies to be associated 
with TRV ≥ 2.5 m/s. Other studies have found that all of their subjects with TRV ≥ 2.5 
m/s had the Hb SS genotype, while their study population included other genotypes 
(Ambrusko et al., 2006; Pashankar et al., 2008). However, our study found that 9 (82%) 
of our subjects with TRV ≥ 2.5 m/s had the Hb SS genotype, while 1 (9%) had the Hb SC 
genotype and 1 (9%) had the Sβ0-thalassemia genotype, and these values were not 
statistically different from subjects with TRV < 2.5 m/s (p = 0.43). One small study also 
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found that 72.7% of their subjects with TRV ≥ 2.5 m/s were on a chronic blood 
transfusion program, while none of our subjects with TRV ≥ 2.5 m/s were on a chronic 
blood transfusion program (Ambrusko et al., 2006). 
 Only 13% of children with SCD in our study had TRV ≥ 2.5 m/s, which is much 
lower than the 30% reported in the literature (Kato et al., 2007). One possible reason 
could be a screening bias in smaller studies summarized in this publication. In our 
institution, echocardiographic screening begins at age 8 years old and is done every 1 to 2 
years, compared to other studies that had variable entry criteria that likely reflected the 
inclusion of more symptomatic patients, resulting in a higher prevalence of TRV ≥ 2.5 
m/s found in these studies (Kato et al., 2007).  
 Differences in rate of TRV ≥ 2.5 m/s between this study and other studies may 
also be caused by HU use. Small studies have found that SCD patients taking HU have 
significantly lower rates of pulmonary hypertension and elevated TRV than SCD patients 
not taking HU; one study found that 9 (35%) of their subjects with TRV ≥ 2.5 m/s were 
on hydroxyurea while another found that 6 (33%) of their subjects with TRV ≥ 2.5 m/s 
were on hydroxyurea (p = 0.01 and p = 0.05 respectively) (Ataga et al., 2004; Ataga et 
al., 2006). Our study found that 6 (55%) of our patients with TRV ≥ 2.5 m/s were taking 
HU, and there was no statistical significance found between those with elevated TRV and 
those without elevated TRV. Other small studies have found a significant reduction in 
TRV while SCD patients were on HU therapy (Olnes et al., 2009; Pashankar et al., 2009). 
In this study, 53 (64%) were prescribed HU, which may partially account for the lower 
prevalence of TRV ≥ 2.5 m/s in this population.  
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Limitations 
 This study is a retrospective longitudinal cohort chart review study, and therefore 
comes with inherent limitations. First, this study was done in a single academic center; 
therefore, the results may not be generalizable to the population of children with SCD. 
Second, not all patients had regular screening echocardiograms, which limits our ability 
calculate the prevalence of TRV in this population of children. Third, not all screening 
echocardiograms documented TRV, making those echocardiograms ineligible for our 
study and making it difficult to follow the progression of TRV in individual study 
subjects. Finally, lab results related to elevated TRV in previous studies, such as LDH 
and indirect bilirubin levels, were not available for analysis in this study (Kato et al., 
2007; Pashankar et al., 2008; Minniti et al., 2009).  
 
Conclusion 
 This study found that 13% of our study population had one or more 
echocardiograms with TRV ≥ 2.5 m/s, which is lower than other studies that have found a 
30% rate of elevated TRV in children with SCD (Kato et al., 2007). While other studies 
have found that an Hb SS genotype, history of ACS, history of sepsis and/or bacteremia, 
history of asthma, history of chronic blood transfusions, low hemoglobin, and increased 
reticulocyte count were associated with TRV ≥ 2.5 m/s in children with SCD, our study 
found that only an increased reticulocyte count was significantly associated TRV ≥ 2.5 
m/s when compared to subjects with TRV < 2.5 m/s (Hagar et al., 2007; Minniti et al., 
2009; Pashankar et al, 2008; Ambrusko et al., 2006; Kato et al., 2007).  
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Boston University School of Medicine (May 2015 – present) 
I performed a longitudinal cohort study chart review examining the prevalence of 
indicators for pulmonary hypertension in children with sickle cell disease. I 
reviewed echocardiogram reports as well as history of sickle cell disease 
complication previously reported to be associated with pulmonary hypertension, as 
well as laboratory values previously reported to be associated with pulmonary 
hypertension.  
Neuroscience and Stem Cell Research, with Dr. Fred Gage 
Salk Institute for Biological Sciences (July 2013 – March 2014) 
I utilized human induced pluripotent stem cell derived neurons and neural 
progenitors in conjunction with in-vivo imaging techniques to study the integration 
of these cells into a functional neural network to create a new mouse model of 
schizophrenia. Experience with tissue culture, viral transduction, murine survival 
surgery with sterile technique and nanoinjection, immunohistochemistry, 
fluorescence imaging, confocal imaging, and 2-photon imaging.  
Marine Biology Research, with Dr. Elena Keeling 
California Polytechnic State University (March 2014 – June 2014)  
I worked with noninjection techniques, cell staining techniques, and confocal 
imaging to study the whole body regenerative capability of the marine invertebrate 
Botrylloides violaceus. 
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Biochemistry Research, with Dr. Lori Robins 
California Polytechnic State University (September 2011 – June 2012) 
I worked with molecular biology and gene expression techniques to express the 
Sma1 gene for a homing endonuclease in hopes to explore the interactions between 
the enzyme and DNA and its potential for gene therapy. Experience with bacterial 
culture, bacterial transformation, spectrophotometry, gel electrophoresis, SDS-
PAGE, and RT-PCR.  
Organic Chemistry Research, with Dr. Hasan Palandoken 
California Polytechnic State University (January 2010 – June 2011) 
I utilized organic synthesis techniques to create a new small molecule and explore 
the potential for a new brain cancer therapy that inhibits the ion exchangers on 
cellular surfaces. Experience with column chromatography, IR spectroscopy, 
carbon NMR, proton NMR, and gas chromatography-mass spectrometry. 
 
Previous Work and Volunteer Experience 
 
Scribe America, ER Scribe (March 2012 – August 2014) 
I worked in the emergency rooms in two hospitals. I attended the patient interviews, 
physical exams, and ER procedures and recorded physician findings and procedures 
on the patient charts. I also worked to find old medical records and radiological 
exams for physician review. 
Teacher’s Assistant Program (September 2010 – June 2011) 
I worked with seventh and eighth grade math and science classes at Fesler Junior 
High School to facilitate learning and promote individual discovery and 
understanding of scientific and mathematical material. 
Growing Grounds Volunteer (April 2010 – June 2010) 
This is an organization from Transitions-Mental Health Association designed to 
provide horticultural therapy for its employees who are all afflicted with a mental 
health issue. While volunteering there it was my job to work along side the 
employees and talk with them, empowering them to express themselves and teach 
me how to take care of the nursery. 
 
